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Uterine leiomyomas are benign tumors that arise from the smooth muscle cells of the 
myometrium under the influence of estrogen and progesterone. Their incidence approaches 
70% in Caucasian women and exceeds 80% in African American women by age 50. A 
quarter of these women suffer from symptoms that require medical attention. As 
leiomyomas impair the quality of life in a large proportion of women, these tumors pose a 
significant health and economic impact. Leiomyomas are heterogeneous in their number, 
size, location, growth rate, histological features, and clinical presentation, as well as in their 
molecular characteristics. 
Multiple distinct genetic alterations lead to the development of these tumors, including 
chromosomal rearrangements affecting high mobility group AT-hook 2 (HMGA2) and 
biallelic inactivation of fumarate hydratase (FH). Moreover, a recent Finnish exome 
sequencing study discovered that most leiomyomas harbor mutations in mediator complex 
subunit 12 (MED12). This breakthrough finding pinpointed the main tumorigenic event 
underlying leiomyomas, but also instigated the demand for further characterization of these 
mutations. Furthermore, the downstream mechanisms of how these genetic aberrations drive 
leiomyoma growth remain elusive. This thesis aimed to study the occurrence and 
characteristics of MED12-mutation-positive and -negative uterine leiomyomas, and to 
elucidate the metabolomic profiles of leiomyomas harboring distinct genetic drivers. 
To determine the frequency and clinical features of MED12 mutations in uterine 
leiomyomas, we screened various sample series for these mutations by Sanger sequencing 
and assessed potential associations between clinical variables and mutation status. This 
work validated the occurrence of MED12 mutations in uterine leiomyomas derived from 
South African women, and demonstrated that these mutations are the main genetic driver of 
leiomyomas regardless of ethnicity. Our results showed that when small leiomyomas are 
also examined, the mutation frequency is as high as 86%, and in the largest leiomyoma 
series thus far with carefully controlled size bias, the mutation frequency was 79%. We 
discovered that MED12 mutations are associated with smaller size, subserosal location, 
conventional histology, and larger number of leiomyomas. In addition, the number of 
mutation-positive leiomyomas was inversely associated with parity, and the number of 
mutation-negative leiomyomas was associated with a history of pelvic inflammatory 
disease. These findings demonstrate the extremely high MED12-mutation frequency and 
their contribution to the observed heterogeneity of uterine leiomyomas. 
Global metabolomic profiling of uterine leiomyoma and corresponding myometrium 
samples revealed that the three main genetic drivers result in differences in metabolic 
profiles; in particular, FH-deficient leiomyomas were distinguishable based on their unique 
profile. We observed shared metabolic changes for all leiomyomas and distinctive 
alterations for FH-deficient and MED12-mutation-positive leiomyomas. The dysregulated 
metabolic pathways identified in this study should be relevant for improving prevention and 




utilized as biomarkers to distinguish between leiomyomas of the different molecular 
subtypes. 
This thesis highlights the role of MED12 mutations and metabolomic alterations in 
leiomyomas, further emphasizing the importance of molecular classification of leiomyomas 
in research, and possibly in clinical practice as well when targeted treatment options emerge. 




REVIEW OF THE LITERATURE 
1. Uterine leiomyomas 
The uterus, an essential organ for the reproduction of eutherian mammals, consists of three 
distinct layers: the inner mucosal lining, the endometrium; the outer serosal layer, the serosa; 
and the thick muscular layer, the myometrium. The myometrium consists of smooth muscle 
cells surrounded by supporting stroma and vasculature, forming a three-layered structure of 
differentially organized muscle fibers designed to contract efficiently during labor. 
Occasionally, myometrial cells start to proliferate abnormally giving rise to benign smooth 
muscle tumors called uterine leiomyomas or fibroids. The pathogenic mechanism 
underlying this aberrant cell proliferation is multifactorial, and different leiomyomas may 
arise through diverse etiologies. In this thesis, the term leiomyoma refers to uterine 
leiomyoma unless otherwise specified. 
1.1. Epidemiology 
Leiomyomas occur in women during their reproductive years with the incidence increasing 
up to menopause. Prevalence estimates of leiomyomas range from 5 to 89% depending on 
the inclusion criteria, screening method, and the size, age, and race of the study population 
(Drayer and Catherino, 2015). According to a study with ultrasonographically confirmed 
cases, Caucasian women have an incidence of 40% by age 35, and nearly 70% by age 50, 
whereas African-American women have an incidence of 60% by age 35, and over 80% by 
age 50 (Baird et al., 2003). Approximately 20 to 50% of affected women are symptomatic 
(Stovall, 2001). Because of the high incidence and morbidity of leiomyomas, they pose an 
enormous socio-economic burden; their estimated annual cost ranges from $6 to $34 billion 
in the USA (Cardozo et al., 2012). 
Leiomyomas affect different racial groups disproportionately. In addition to a higher 
incidence of leiomyomas in African-American women, these women display a younger age 
at diagnosis and at hysterectomy, larger and more numerous leiomyomas, as well as more 
severe symptoms than Caucasian women (Kjerulff et al., 1996; Faerstein et al., 2001a; Baird 
et al., 2003; Huyck et al., 2008; Laughlin et al., 2009; Moorman et al., 2013; Stewart et al., 
2013; Drayer and Catherino, 2015). Apart from African ancestry, leiomyomas seem to affect 
other racial groups as frequently as Caucasian women (Marshall et al., 1997; Laughlin et 
al., 2009; Zimmermann et al., 2012). Although both genetic and environmental factors are 
likely to underlie this racial disparity, the fundamental mechanisms remain unclear 
(Catherino et al., 2013). 
The development of leiomyomas depends highly on female steroid hormones, as these 
tumors do not occur before puberty and typically regress after menopause (Ross et al., 1986; 
Cramer and Patel, 1990; Moroni et al., 2015). During pregnancy, leiomyomas may grow 
especially during the first trimester, but most leiomyomas eventually shrink and, after 
parturition, may become undetectable (Laughlin et al., 2010; Ciavattini et al., 2016). Many 
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of the risk factors for leiomyomas are related to exposure to estrogen and progesterone 
(Table 1). In addition, genetic, lifestyle, and environmental factors influence the risk of 
developing leiomyomas (Table 1). One of the main challenges in epidemiological 
leiomyoma research is obtaining leiomyoma-free controls due to their high prevalence in 
asymptomatic women and their clinical appearance during the late reproductive years. 
Further research is required to gain a better understanding of how these risk factors influence 
leiomyoma development. 
1.2. Clinical course 
Leiomyomas can be detected in a pelvic exam and the diagnosis can be confirmed by 
transvaginal sonography (Stewart et al., 2016). Other imaging techniques, including 
transabdominal or saline-infusion sonography and magnetic resonance imaging, may be 
needed to accurately assess the size, number, location, or vascularity of leiomyomas 
(McLucas, 2008; Stewart et al., 2016). Differential diagnoses for leiomyomas include 
leiomyosarcomas, adenomyosis or adenomyomas, ovarian masses, and endometrial polyps 
(McLucas, 2008). 
The range and severity of symptoms from leiomyomas depend highly on the number, 
location, and size of the tumors (Stovall, 2001; Gupta et al., 2008). Patients may have 
anything from a single tumor to innumerable leiomyomas of different sizes; an affected 
uterus contains on average 8 to 9 of these tumors, and they may commonly be 10 to 20 cm 
in diameter (Cramer and Patel, 1990; Stewart et al., 2016). Leiomyomas can grow anywhere 
within the uterine wall, the cervix, or the uterine ligaments, and can protrude into the uterine 
cavity or outward into the peritoneal cavity while attached to the myometrium by a peduncle 
(Figure 1) (McLucas, 2008). Leiomyomas can be classified based on their location relative 
to the myometrial layers: submucosal leiomyomas underlie the endometrium, intramural lie 
within the myometrium, and subserosal underlie the serosa. A single uterus may harbor 
different types of leiomyomas at the same time, and the tumors may grow or regress at 
different rates in the same uterine environment (Peddada et al., 2008). 
The most frequent leiomyoma-related symptom is abnormal uterine bleeding usually 
presenting as heavy menstrual bleeding, which may also be prolonged or irregular, involve 
dysmenorrhea, and lead to iron deficiency anemia (Stovall, 2001; Gupta et al., 2008). 
Abnormal bleeding is particularly associated with submucosal leiomyomas. Affected 
postmenopausal women may also suffer from bleeding symptoms, especially related to 
hormone-therapy use. Patients with leiomyomas frequently experience pain in the pelvis, 
abdomen, or back. The pain can be cyclic or non-cyclic, or dyspareunia. Necrotic or 
degenerative leiomyomas may lead to acute abdominal pain. The enlarged uterus or a large, 
leiomyoma may press the surrounding organs leading to pelvic or abdominal discomfort, 
urinary frequency or retention, hydronephrosis, or bowel disturbance. Leiomyomas may 
cause infertility by, for example, blocking the fallopian tubes or distorting the uterine cavity 
(Stovall, 2001). Women with leiomyomas have an increased risk of cesarean section, 
preterm birth, and other pregnancy complications (Stovall, 2001; Gupta et al., 2008). The 
majority of women with symptomatic leiomyomas display multiple concurrent symptoms 
(Gupta et al., 2008).  




Table 1. Leiomyoma risk factors from epidemiological studies. 
Factor Reference(s) 
Increased risk  
African-American origin (Kjerulff et al., 1996; Marshall et al., 1997; Faerstein et al., 2001a; Baird et al., 2003; Laughlin et al., 2009; Templeman et al., 2009; Ott et al., 2014) 
Age up to menopause (Ross et al., 1986; Marshall et al., 1997; Baird et al., 2003; Ott et al., 2014; Sommer et al., 2015) 
Alcohol (Marshall et al., 1997; Wise et al., 2004b; Templeman et al., 2009) 
Carotid intima-media thickness (Aksoy et al., 2014) 
Cosmetics and other chemicals (Shen et al., 2013) 
Family history of leiomyomas (Vikhlyaeva et al., 1995; Lumbiganon et al., 1996; Sato et al., 2002; Templeman et al., 2009) 
Food additives (Shen et al., 2013) 
Hormone therapy (Templeman et al., 2009; Sommer et al., 2015; Uimari et al., 2016) 
Hypertension (Faerstein et al., 2001b; Boynton-Jarrett et al., 2005; Takeda et al., 2008; Templeman et al., 2009) 
Infertility (Parazzini et al., 1996; Marshall et al., 1997; 1998; Templeman et al., 2009) 
Longer time since last birth (Marshall et al., 1997; 1998; Wise et al., 2004a; Terry et al., 2010) 
Metabolic syndrome (Uimari et al., 2016) 
Nulliparity (Parazzini et al., 1988; 1996; Wise et al., 2004a; Parazzini, 2006) 
Obesity/body mass index/ 
waist-to-hip ratio 
(Ross et al., 1986; Lumbiganon et al., 1996; Marshall et al., 1997; Sato et al., 1998; Faerstein et 
al., 2001a; Wise et al., 2005; Parazzini, 2006; Takeda et al., 2008; Templeman et al., 2009; 
Sommer et al., 2015; Uimari et al., 2016) 
Omega-3 (n-3) polyunsaturated 
fatty acids (Wise et al., 2014) 
Pelvic inflammatory disease (Faerstein et al., 2001b) 
Phthalates/plastic products (Huang et al., 2010; Shen et al., 2013) 
Polycystic ovary syndrome (Wise et al., 2007) 
Prenatal diethylstilbestrol (Baird and Newbold, 2005; Mahalingaiah et al., 2014) 
Psychological stress/depression (Vines et al., 2010; Boynton-Jarrett et al., 2011; Wise et al., 2015) 
Red meat (Chiaffarino et al., 1999) 
Soybean milk (Shen et al., 2013) 
Thyroid disease (Ott et al., 2014) 
Unfavorable serum lipid profile (Aksoy et al., 2014; Uimari et al., 2016) 
Vitamin D deficiency (Baird et al., 2013) 
Decreased risk  
Breast feeding (Lumbiganon et al., 1996; Terry et al., 2010) 
Dairy (Wise et al., 2010) 
Diabetes (Wise et al., 2007; Templeman et al., 2009; Velez Edwards et al., 2017) 
Dioxin (Eskenazi et al., 2007) 
Exercise (Baird et al., 2007) 
Fruits and vegetables (Chiaffarino et al., 1999; Wise et al., 2011) 
Irregular menstrual cycle (Terry et al., 2010) 
Later age at first birth (Marshall et al., 1997; 1998; Wise et al., 2004a; Templeman et al., 2009; Terry et al., 2010) 
Later age at last birth (Ross et al., 1986; Lumbiganon et al., 1996; Terry et al., 2010) 
Later age at menarche (Lumbiganon et al., 1996; Marshall et al., 1997; 1998; Faerstein et al., 2001a; Wise et al., 2004a; Terry et al., 2010; Velez Edwards et al., 2013) 
Longer menstrual cycle length (Terry et al., 2010) 
Menopause (Ross et al., 1986; Parazzini et al., 1988; Parazzini, 2006; Templeman et al., 2009; Sommer et al., 2015) 
Parity (Ross et al., 1986; Parazzini et al., 1988; 1996; Lumbiganon et al., 1996; Marshall et al., 1998; Sato et al., 2002; Wise et al., 2004a; Parazzini, 2006; Terry et al., 2010; Uimari et al., 2016) 
Progestin-only injectables (Lumbiganon et al., 1996; Wise et al., 2004a) 
Smoking (Ross et al., 1986; Parazzini et al., 1988; 1996; Lumbiganon et al., 1996; Templeman et al., 2009) 
Inconsistent risk effect  
Abortions (Lumbiganon et al., 1996; Parazzini et al., 1996) 
Oral contraceptives (Ross et al., 1986; Lumbiganon et al., 1996; Parazzini et al., 1996; Marshall et al., 1997; 1998; Faerstein et al., 2001a; Wise et al., 2004a) 
Vitamin A (Martin et al., 2011; Wise et al., 2011) 
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The choice of treatment depends on the patient’s age, symptoms, reproductive wishes, 
beliefs, and other medical conditions, as well as the location, size, and number of tumors. 
The selective progesterone receptor agonist ulipristal acetate, which was recently approved 
for intermittent use in Europe, has shown great promise as an effective treatment for 
leiomyomas. In most patients, but not all, this drug reduces the size of leiomyomas and 
controls the bleeding symptoms effectively. The effects of its long-term intermittent use are 
currently under investigation. Gonadotropin releasing hormone agonists also reduce the size 
of leiomyomas and induce amenorrhea, but due to severe side effects related to hormonal 
suppression, they are prescribed only preoperatively to facilitate less invasive surgery or to 
correct iron deficiency anemia. Other medical therapy options provide merely symptomatic 
relief. Hormonal contraceptives and levonorgestrel-releasing intrauterine devices alleviate 
the pattern and volume of menstrual bleeding. In addition, antifibrinolytics, such as 
tranexamic acid, and non-steroidal anti-inflammatory drugs reduce heavy bleeding. As 
medical therapies leave room for improvement, surgery is frequently used. Hysterectomy is 
currently the only definitive treatment; leiomyomas are the indication of one-third to half of 
all hysterectomies. Less invasive surgical options include myomectomy, uterine artery 
embolization, focused-ultrasound surgery, and radiofrequency ablation. Minimally invasive 
techniques, such as endometrial ablation and hysteroscopic electroresection of submucosal 
leiomyomas, are used to control heavy bleeding. (Stewart et al., 2016). 
The heterogeneity in the clinical presentation, growth patterns, and drug responses of 
leiomyomas suggests that complex biological mechanisms underlie the development and 
growth of these lesions. 
 
Figure 1. The female reproductive system and different types of leiomyomas classified according to their 
location relative to the myometrial layers. Modified July 24th, 2017, from informedhealth.org web site 
(https://www.informedhealth.org/uterine-fibroids.2622.en.html) with the permission of the copyright holder. 





Leiomyomas are typically characterized as firm, whorled nodules with a white cut surface 
(Oliva et al, 2014). They are well circumscribed due to a surrounding pseudocapsule and 
compressed muscle fibers separating them from the adjacent myometrium. Leiomyomas 
consist mainly of four different cell types: smooth muscle cells, vascular smooth muscle 
cells, fibroblasts, and leiomyoma-associated fibroblasts (Holdsworth-Carson et al., 2014). 
Histologically, the abnormally organized smooth muscle cells are characterized by obscure 
borders, eosinophilic cytoplasm, and cigar-shaped nuclei with small conspicuous nucleoli 
and little mitotic activity (Oliva et al, 2014). The cells are surrounded by abundant 
disorganized extracellular matrix (ECM) consisting of collagen, proteoglycans, and 
fibronectin (Malik et al., 2010). Histological features of leiomyomas may vary in terms of 
infarct-type necrosis, cellularity, hyalinization, and calcification (Oliva et al, 2014). 
Approximately 10% of leiomyomas display some features of malignant neoplasms, such as 
increased cellularity, mitotic activity, or nuclear atypia; these leiomyomas are classified as 
histopathological variants (Table 2) (Oliva et al, 2014). It is unclear whether leiomyomas 
precede their malignant counterpart, leiomyosarcoma, which is an extremely rare aggressive 
cancer type with poor prognosis. The majority of leiomyosarcomas are believed to arise de 
novo, and if malignant transformation does occur, it is very rare (Gupta et al., 2008). 
Table 2. Features of different subtypes of uterine smooth muscle tumors (Oliva et al, 2014). 
Subtype Characteristics 
Histopathological leiomyoma variants 
Cellular leiomyoma Higher cellularity when compared to the adjacent myometrium 
Epithelioid leiomyoma “Epithelial-like” rounded or polygonal cells. 
Hydropic leiomyoma Prominent zonal edema. 
Leiomyoma with apoplectic change Zones of hemorrhagic infarction surrounded by hypercellular areas. 
Leiomyoma with bizarre nuclei Groups of bizarrely shaped cells displaying nuclear atypia 
Lipoleiomyoma Adipocytes intermixed with the smooth muscle cells. 
Mitotically active leiomyoma Mitotic activity of >10 mitotic figures per 10 high-power fields 
Myxoid leiomyoma Myxoid acid-mucin stroma surrounding sparsely occurring cells. 
Leiomyomas with unusual growth patterns 
Cotyledonoid dissecting leiomyoma Irregular dissection of bland smooth muscle cells within the myometrium. 
Diffuse leiomyomatosis Innumerable, ill-defined, confluent, hypercellular tumors throughout the myometrium. 
Intravenous leiomyomatosis Worm-like growth of smooth muscle within vascular spaces 
Metastasizing leiomyoma Extrauterine; lungs are most frequently affected organ; related to a history of leiomyomas.  
Intermediate/malignant smooth muscle tumors 
Smooth muscle tumor of uncertain 
malignant potential Combination of features of leiomyoma and leiomyosarcoma. 
Leiomyosarcoma Malignant smooth muscle tumors, typically soft, fleshy, necrotic, and hemorrhagic with 
irregular margins that may display spindle cell, epithelioid, or myxoid morphology. 
 
 




Human tumors arise through a multistep process in which a single cell, or a group of cells, 
acquires genetic or epigenetic mutations that modify important cellular functions such as 
cell division, differentiation, or life span, leading to uncontrolled proliferation. Genes that 
commonly drive tumorigenesis are typically classified as oncogenes or tumor suppressor 
genes (Vogelstein and Kinzler, 2004). Oncogenes are activated by mutations leading to 
enhanced or renewed function that promotes an aberrant phenotype, whereas tumor 
suppressor genes are inactivated by mutations overcoming their normal inhibitory effect on 
cell proliferation. Genes that facilitate tumor development through genome integrity are 
called stability genes: their inactivation leads to an increased mutation rate and additional 
tumorigenic changes. 
Carcinogenesis forms a continuum in which cells transform from benign to more malignant 
by accumulating mutations, which are either neutral passenger mutations or tumor-
promoting driver mutations that provide a selective advantage to the cells (Vogelstein et al., 
2013; Vogelstein and Kinzler, 2015). During tumor progression, neoplastic cells acquire 
distinct tumor-promoting properties known as the hallmarks of cancer (Hanahan and 
Weinberg, 2011). The hallmarks include sustaining proliferative signaling; evading growth 
suppressors, apoptosis, and immune destruction; enabling replicative immortality; inducing 
angiogenesis; adapting cellular metabolism; and eventually activating invasion and 
metastasis. The acquisition of these traits is enabled by genomic instability and tumor-
promoting inflammation. Benign tumors, which are typically more stable on the genetic 
level, may possess many of these hallmarks but lack the capability to spread. Accumulation 
of mutations during tumor evolution leads to intratumor heterogeneity, where different cell 
subpopulations that harbor unique genetic alterations may differ phenotypically and 
functionally. Contributing to the intratumor heterogeneity, a subpopulation of cancer cells 
possesses stem-like properties enabling them to self-renew and differentiate into various 
cell types (Hanahan and Weinberg, 2011; Kreso and Dick, 2014). These cancer stem cells 
may initiate and drive tumor growth. In addition to neoplastic cells, tumors contain stroma, 
vasculature, immune cells, and a variety of other cell types that form the tumor 
microenvironment (Whiteside, 2008; Hanahan and Weinberg, 2011). The 
microenvironment contributes to the tumor heterogeneity, supports tumor growth and 
invasion, and enables the tumor to escape host immunity. 
Tumorigenesis is a sum of genetic, environmental, and lifestyle factors (Hemminki et al., 
2006). The majority of tumors occur sporadically, but 1 to 10% of cancers arise due to high-
penetrance germline mutations that introduce a high risk for an individual to develop tumors 
(Nagy et al., 2004; Hemminki et al., 2006). Typically, hereditary tumor syndromes are 
inherited in an autosomal dominant manner and caused by heterozygous germline mutations 
in tumor suppressor genes (Nagy et al., 2004). Syndromic tumors develop when somatic 
mutations inactivate the wild-type allele. Common low-penetrance variants may jointly 
increase the risk of developing tumors together with environmental factors (Antoniou et al., 
2002; Hemminki et al., 2006; Zheng et al., 2008). Somatic mutations arise spontaneously 
through DNA replication, repair, and recombination errors during cell division, or they can 
be caused by mutagens that can be endogenous like hormones, or exogenous, such as 




tobacco, chemicals, and ultraviolet light. In addition, infectious agents, such as human 
papilloma virus, may initiate tumorigenesis. Tumor progression and growth requires 
proliferative signals provided by, for example, hormones and growth factors. 
2.1. Leiomyomagenesis 
Leiomyomas are monoclonal and multiple nodules within a single uterus generally have a 
unique origin, although some concurrent leiomyomas have displayed identical 
chromosomal changes indicating a shared origin (Linder and Gartler, 1965; Townsend et 
al., 1970; Nilbert and Heim, 1990; Bonatz et al., 1998; Mehine et al., 2013; 2015; 
Holdsworth-Carson et al., 2014). As leiomyomas are monoclonal but consist of multiple 
cell types, leiomyomas must originate from a single parental cell with multipotent stem cell 
properties, possibly from a transformed myometrial stem cell (Figure 2) (Mas et al., 2012; 
Ono et al., 2012). The triggers that may transform a myometrial stem cell into a leiomyoma 
stem cell are likely to be genetic or epigenetic changes potentially induced and promoted 
by a preceding condition or injury in the uterus, such as abnormal estrogen and progesterone 
signaling, ischemia, inflammation, or viral infections (Bullerdiek, 1999; Flake et al., 2003; 
Wegienka, 2012). Leiomyomas contain these cells with stem-like properties that may have 
the potential to differentiate into all the cell types found in these tumors, possibly through 
estrogen and progesterone induced paracrine activation of Wnt/β-catenin signaling (Mas et 
al., 2012; Ono et al., 2012; 2013).  
Estrogen and progesterone are essential promoters of leiomyomas. The molecular 
mechanism underlying this growth stimulation remains elusive, but it seems to involve 
altered activity of aromatase and 17β-hydroxysteroid dehydrogenase that lead to 
accumulation of estradiol and thereby upregulation of estrogen and progesterone receptors. 
The tumor promoting effect of estrogen may arise through induction of progesterone 
receptors and thus progesterone would be the main regulator of leiomyoma growth. 
Essentially, estrogen and progesterone upregulate various growth factors and activate 
signaling pathways that enhance cell proliferation and ECM formation. The promotion of 
leiomyoma development is likely to result from the interaction of these hormones and other 
factors. (Flake et al., 2003; Borahay et al., 2015; Stewart et al., 2016). 
In addition to steroid hormones, reduced levels of retinoic acid (RA) and vitamin D may 
play a role in leiomyoma development (Borahay et al., 2015; Brakta et al., 2015; Stewart et 
al., 2016). Vitamin D3 regulates leiomyoma growth potentially through altering the levels 
of ECM degrading matrix metalloproteinases, vitamin D receptors, ECM proteins, as well 
as estrogen and progesterone receptors leading to induction of apoptosis and modulation of 
the ECM. RA inhibits proliferation, induces apoptosis, and reduces expression of ECM 
components in leiomyoma cells (Gilden et al., 2012; Borahay et al., 2015; Stewart et al., 
2016). 
In comparison to the normal myometrium, leiomyomas display altered levels of several 
growth factors including transforming growth factor β, acidic and basic fibroblast growth 
factor, insulin-like growth factor, platelet-derived growth factor, epidermal growth factor, 
and vascular endothelial growth factor. These growth factors can activate signaling 
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pathways such as PI3K/AKT/mTOR, MAPK/ERK, and transforming growth factor β/Smad 
resulting in the promotion of cell proliferation and survival, as well as the synthesis of DNA, 
protein, and the ECM. (Borahay et al., 2015). 
 
 
Figure 2. Schematic view of leiomyomagenesis. A) Myometrial stem cells account for the proliferation of the 
smooth muscle cells of the normal myometrium. These stem cells express lower levels of estrogen receptor 
(ERα) and progesterone receptor (PR) than the mature smooth muscle cells. Thus, estrogen and progesterone 
potentially induce stem cell self-renewal and proliferation in a paracrine fashion. B) Leiomyomas (fibroids) 
seem to originate from a myometrial stem cell that has been transformed into a leiomyoma stem cell possibly 
by a genetic hit. This leiomyoma stem cell has the potential to self-renew and proliferate until it differentiates 
into a mature leiomyoma cell. C) The uncontrolled proliferation of the self-renewing leiomyoma stem cell 
results in the formation and growth of a leiomyoma. Reproduced with permission from Bulun 2013, Copyright 
Massachusetts Medical Society. 




2.2. Genetics of leiomyomas 
Like most, if not all, human neoplasms, leiomyomas are a genetic disease. A genetic 
component is evident as leiomyomas are a manifestation of some genetic tumor 
predisposition syndromes (Hobert and Eng, 2009; Lehtonen, 2011; Hulsebos et al., 2014). 
Racial disparity, familial aggregation, and twin studies suggest the presence of genetic 
susceptibility to leiomyomas as well (Vikhlyaeva et al., 1995; Kjerulff et al., 1996; Marshall 
et al., 1997; Luoto et al., 2000; Faerstein et al., 2001a; Sato et al., 2002; Baird et al., 2003; 
Huyck et al., 2008; Moorman et al., 2013; Stewart et al., 2013; Drayer and Catherino, 2015). 
Moreover, non-random somatic mutations have been observed in leiomyomas (Lehtonen et 
al., 2004; Sandberg, 2005a; Mäkinen et al., 2011). The genetic background of leiomyomas 
is diverse, suggesting that multiple different mechanisms lead to their development. 
Leiomyomas display epigenetic alterations involving DNA methylation, histone 
modification, and microRNAs, but their roles in leiomyomagenesis remain largely unclear 
(Yang et al., 2016). 
2.2.1. Genetic predisposition 
Leiomyomas are associated with tumor predisposition syndromes including Cowden 
syndrome, Schwannomatosis, and hereditary leiomyomatosis and renal cell cancer 
(HLRCC), caused by heterozygous germline mutations in phosphatase and tensin homolog 
(PTEN), SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily B, member 1 (SMARCB1), and fumarate hydratase (FH), respectively (Hobert 
and Eng, 2009; Lehtonen, 2011; Hulsebos et al., 2014). These high penetrance 
predisposition genes explain only a minor proportion of the estimated heritability of 
leiomyomas, however. 
The most prominent of these syndromes, in regards to leiomyomas, is HLRCC, which is 
characterized by skin and uterine leiomyomas as well as increased risk for highly aggressive 
papillary type II renal cell cancer (Lehtonen, 2011). The risk of renal cell cancer is 
approximately 20%, whereas the penetrance for leiomyomas is nearly complete. HLRCC-
related leiomyomas entail a more severe clinical phenotype as they emerge at an earlier age, 
are more numerous, and lead to symptoms more often than sporadic leiomyomas. These 
syndromic leiomyomas harbor atypical histological features including increased cellularity, 
multinucleated cells, and nuclear atypia with prominent orangeophilic nucleoli surrounded 
by a perinuclear halo, as well as hemangiopericytoma-like vessels (Oliva et al, 2014).  
Genome-wide linkage, association, and admixture mapping studies have identified multiple 
low-penetrance predisposition loci for leiomyomas, but few have been validated by 
replication studies (Table 3) (Cha et al., 2011; Eggert et al., 2012; Wise et al., 2012; 2016; 
Edwards et al., 2013; Aissani et al., 2015; Zhang et al., 2015; Bondagji et al., 2017). 
Pinpointing the causative variants within these chromosomal loci and understanding the 
mechanisms by which these variants increase leiomyoma risk requires further research. 
Challenges with genetic association studies are the same as with epidemiological studies: 
the high incidence of asymptomatic leiomyomas and their relatively late age of onset. 
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Table 3. Low-penetrance predisposition loci for leiomyomas. 
Chromosome Risk variant/locus Candidate/nearby gene(s) Population(s) Reference(s) 
1q42.2 rs7546784 PCNXL2 American (Zhang et al., 2015) 
2q32.2 rs256552 PMS1 American (Zhang et al., 2015) 
3p21.31 169 614-76 307 730 - Caucasian (Eggert et al., 2012) 
10p11.21 9 632 527-72 985 946 COL13A1 Caucasian (Eggert et al., 2012) 
10q24.33 rs7913069 SLK, OBFC1 Japanese (Cha et al., 2011) 
11p15.5 rs2280543 ODF3, BETL1, RIC8A, SIRT3 Japanese, Caucasian 
(Cha et al., 2011; Edwards et 
al., 2013) 
17q25.3 rs4247357 FASN, CCDC57, SLC16A3 Caucasian (Eggert et al., 2012) 




(Cha et al., 2011; Edwards et 
al., 2013; Aissani et al., 
2015; Bondagji et al., 2017) 
 
2.2.2. Somatic chromosomal aberrations 
According to cytogenetic studies, 40% of leiomyomas harbor chromosomal aberrations 
(Table 4) (Sandberg, 2005a; Mitelman et al. 2017). These chromosomally abnormal tumors 
tend to be larger in size, less frequently submucosal, and histologically more cellular and 
mitotically active than chromosomally normal leiomyomas (Sandberg, 2005a). Whether the 
chromosomal abnormalities are primary or secondary changes remains to be established, 
although some of them, such as translocations involving 12q15, occur clonally, suggesting 
that they are initiating driver events, whereas some, such as 7q22 deletions, may be 
subclonal and co-occur with other chromosomal abnormalities, suggesting that they are 
secondary events involved in tumor progression rather than initiation (Pandis et al., 1990; 
Xing et al., 1997). 
Table 4. Recurrently altered chromosomal loci in leiomyomas (Mitelman et al. 2017). 
Chromosome Change(s) Putative target gene(s) 
Estimated proportion 
of leiomyomas (%) Reference(s) 
1p36 Translocation/Deletion AJAP1, NPHP4 2 (van Rijk et al., 2009) 
1q43 Deletion FH <1 (Tomlinson et al., 2002) 
3q Deletion - 3 - 
6p21 Translocation HMGA1 3 (Nezhad et al., 2010) 
7q22 Deletion/Inversion/Translocation CUX1 6 (Moon et al., 2002) 
10q22 Translocation/Deletion KAT6B 2 (Moore et al., 2004) 
12q15 Translocation/Inversion/Trisomy HMGA2 10 (Schoenmakers et al., 1995) 
14q24 Translocation RAD51B 9 (Schoenmakers et al., 1999) 
19q Deletion - 1 - 
22q Deletion/Monosomy DEPDC5 2 (Mehine et al., 2015) 
X Microdeletions COL4A5/6, IRS4 1 (Mehine et al., 2013; 2016) 
 
  




2.2.3. High mobility group AT-hook 2 (HMGA2) 
The target gene of the most frequent rearrangements in leiomyomas is high mobility group 
AT-hook 2 (HMGA2) on chromosome 12q15 (Schoenmakers et al., 1995; Fusco and Fedele, 
2007). Translocations involving 12q15 result in increased expression of HMGA2, 
potentially through acquisition of an active enhancer or promoter, or alternatively through 
loss of the 3’UTR of HMGA2, which contains binding sites for let-7 microRNAs that 
directly inhibit HMGA2 expression (Quade et al., 2003; Klemke et al., 2009; 2010). 
Upregulation of HMGA2 may also derive from reduced expression of let-7 in leiomyomas 
(Wang et al., 2007; Peng et al., 2008; Klemke et al., 2009). Translocations and 
overexpression of HMGA2, as well as low let-7 expression, associate with larger leiomyoma 
size, suggesting that HMGA2 contributes to tumor growth (Sandberg, 2005a; Wang et al., 
2007; Peng et al., 2008). In addition to leiomyomas, HMGA2 rearrangements occur in most 
benign tumor types of mesenchymal origin, for example, in fibroadenomas of the breast 
(Fusco and Fedele, 2007). HMGA2, which indirectly regulates gene expression by binding 
to AT-rich DNA sequences and thereby alters chromatin structure, is normally expressed 
during embryonic development and is generally silenced in differentiated adult tissues. The 
tumor-driving mechanism of HMGA2 is incompletely understood, although it probably 
relates to its role in regulating gene expression and thereby in controlling crucial cellular 
functions, such as proliferation. The most frequent translocation partner of 12q15 is 14q24, 
affecting RAD51 paralog B (RAD51B), which encodes for a repair protein of DNA-double-
strand breaks (Schoenmakers et al., 1999). Whether RAD51B contributes to 
leiomyomagenesis is unclear. 
2.2.4. Fumarate hydratase (FH) 
In addition to HLRCC-related leiomyomas, FH mutations underlie 1% of sporadic 
leiomyomas (Lehtonen et al., 2004). Both hereditary and sporadic tumors display point 
mutations or deletions in both alleles of FH resulting in FH deficiency (Lehtonen et al., 
2004; Lehtonen, 2011). FH is a tricarboxylic acid (TCA) cycle enzyme that catalyzes the 
conversion of fumarate into malate. FH deficiency leads to truncation of the TCA cycle and 
accumulation of fumarate (Pollard et al., 2005). Accumulated fumarate spontaneously 
reacts with cysteine sulfhydryl groups to form S-(2-succinyl)cysteine, a reaction called 
succination (Kinch et al., 2011). One of the proteins succinated by the accumulated fumarate 
is kelch-like ECH-associated protein 1 (KEAP1), which is a negative regulator of 
transcription factor Nuclear factor erythroid 2-related factor 2 (NRF2). NRF2, a master 
regulator of the antioxidant response, is normally activated under oxidative stress, but its 
continuous activation may drive tumorigenesis (Gorrini et al., 2013). Additionally, fumarate 
accumulation leads to stabilization of hypoxia-inducible factor 1-α (HIF-1-α) through the 
inhibition of HIF prolyl hydroxylases that degrade HIF-1-α (Isaacs et al., 2005; Pollard et 
al., 2005). HIF-1-α is a transcription factor that under low-oxygen conditions activates 
target genes involved in vascularization, glycolysis, glucose transport, cell survival, and 
metastasis (Powis and Kirkpatrick, 2004). 
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2.2.5. Mediator complex subunit 12 (MED12) 
Owing to the recent evolution of next-generation sequencing techniques, exome sequencing 
of 18 leiomyomas and subsequent screening of additional 207 leiomyomas altogether 
derived from 80 Finnish patients revealed mediator complex subunit 12 (MED12) mutations 
in 71% of the leiomyomas. All of the detected mutations clustered in exon 2 or in the 
preceding intron-exon boundary; this region is highly evolutionarily conserved. The 
majority of mutations were missense mutations affecting codon 44 (69%), yet missense 
mutations affecting codons 36 (7%) and 43 (2%) also occurred. Ten (6%) leiomyomas 
displayed an intronic point mutation eight base pairs upstream of exon 2 resulting in the 
addition of two amino acids to the protein product. The rest of the mutations (16%) were 
insertion-deletions and were predicted to result in an in-frame protein product. No additional 
mutations emerged when all MED12 exons were sequenced in 20 mutation-negative and 10 
mutation-positive leiomyomas. Mutations were heterozygous, but cDNA sequencing of 16 
tumors showed that the tumors expressed mainly the mutated form of MED12. Sequencing 
of the corresponding normal myometrium samples confirmed the somatic origin of the 
mutations. MED12-mutation-positive leiomyomas were non-randomly distributed among 
the patients and were significantly smaller than mutation-negative tumors. Taken together, 
these data suggest that mutated MED12 drives leiomyomagenesis. (Mäkinen et al., 2011). 
The 45 exons of MED12 span 24 kilobases on chromosome Xq13. MED12 is generally 
continuously expressed across human tissues (Philibert and Madan, 2007). The MED12 
protein consists of 2177 amino acids comprising four domains and three conserved sequence 
motifs (Figure 3) (Philibert and Madan, 2007; Finn et al., 2016). One of these conserved 
motifs, Med12-PQL, contains binding sites for β-catenin, the transcription factors Sox9 and 
Gli3, and the histone methyltransferase G9a (Zhou et al., 2002; 2006; Kim et al., 2006; Ding 
et al., 2008). MED12 is a part of an evolutionarily conserved multiprotein complex called 
the Mediator (Allen and Taatjes, 2015). The Mediator consists of three core domains: the 
tail, middle, and head, and a detachable kinase module called the cyclin-dependent kinase 
(CDK) 8 module, which comprises MED12, mediator complex subunit 13 (MED13), Cyclin 
C, and CDK8 or alternatively CDK19 (Figure 3). The Mediator regulates basal transcription 
by acting as a bridge between RNA polymerase II and transcription factors. The attachment 
of the CDK8 module to the core Mediator controls the formation of the preinitiation 
complex and thereby initiation of transcription. The CDK8 module also indirectly regulates 
transcription by phosphorylating target molecules. Apart from its function as part of the 
CDK8 module, MED12 plays a role in multiple developmental pathways including Wnt and 
Sonic Hedgehog signaling (Zhou et al., 2006; Rocha et al., 2010). In addition, MED12 links 
G9a with RE1 silencing transcription factor (REST) to silence its neuronal target genes 
(Ding et al., 2008). Germline mutations affecting the leucine-serine-rich and proline-
glutamine-leucine-rich domains of MED12 cause a broad spectrum of X-linked intellectual 
disability syndromes (Graham and Schwartz, 2013). The role of MED12 mutations in 
human tumors requires further elucidation.  





Figure 3. Schematic view of the MED12 protein and the Mediator. A) MED12 consists of 2177 amino acids 
comprising four domains: a leucine-rich (L) domain, a leucine-serine-rich (LS) domain, a proline-glutamine-
leucine-rich (PQL) domain, and a glutamine-rich opposite paired (OPA) domain. Three sequence motifs, 
Med12, Med12-LCEWAV, and Med12-PQL, are conserved in eukaryotes. B) The Mediator consists of 30 
subunits that form the core mediator and a detachable CDK8 module.
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AIMS OF THE STUDY 
1. To study the occurrence of MED12 mutations in leiomyomas from women with 
African ancestry 
2. To study the frequency of MED12 mutations in an unselected sample set of 
leiomyomas 
3. To study the clinical features of MED12-mutation-positive and -negative 
leiomyomas 
4. To characterize the metabolomes of leiomyomas harboring distinct genetic drivers




MATERIALS AND METHODS 
1. Ethics approval (I-IV) 
The Human Research Ethics Committee, Cape Town, South Africa approved Study I. The 
Ministry of Social Affairs and Health and the Ethics Committee for gynecology and 
obstetrics, pediatrics, and psychiatry of the Hospital District of Helsinki and Uusimaa, 
Finland approved Studies I-IV. Patients from the B, My, My1000, My5000, My6000, and 
N series signed an informed consent (I-IV). The director of the health-care unit approved 
the acquisition of anonymous samples in the M series (IV). 
2. Samples (I-IV) 
For Study I, we obtained genomic DNA from 28 fresh frozen leiomyomas and 14 
corresponding normal myometrial tissue samples derived from 18 women with African 
ancestry from the Department of Obstetrics and Gynecology, Faculty of Health Sciences, 
University of Cape Town/Groote Schuur Hospital, Cape Town, South Africa (Table 5). 
Information on the patients’ age at diagnosis, total number of leiomyomas, and tumor size 
accompanied the samples. 
Table 5. Summary of samples included in Studies I-IV. 
Series Patients Leiomyomas Time frame Hospital Clinical data available Population (n) 
Study I       
African 18 28 not available Groote Schuur Hospital Yes Black African (6)/ Colored (12) 
Study II        
Consecutive set      
My5000 14 103 2013 Jorvi hospital Yes Finnish (13)/  Romanian (1) 
Unselected set      
My1000 11 54 2012 Women’s hospital Yes Finnish (10)/ Swedish (1) 
My5000 4 22 2013 Jorvi hospital Yes Finnish (4) 
Study III       
My6000 244 763 2013-2015 Kätilöopisto Yes Finnish (219)/ non-Finnish (25) 
Study IV       
B7 (HLRCC) 1 1 2002 Women’s hospital Yes Finnish (1) 
N7 (HLRCC) 1 1 2007 Turku University Hospital Yes Finnish (1) 
M 6 9 2001-2002 Women’s hospital No not available (6) 
My 3 4 2003-2008 Women’s hospital Yes Finnish (3) 
My5000 1 1 2013 Jorvi hospital Yes Finnish (1) 
My6000 5 9 2013-2015 Kätilöopisto Yes Finnish (5) 
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For Studies II-IV, leiomyoma and corresponding normal myometrial tissue samples were 
collected as fresh frozen from patients undergoing hysterectomy for any medical indication 
(Table 5). For Study II, we set out to collect all tumor nodules from unselected series of 
patients. The My1000 series constituted 54 leiomyomas from 11 patients operated on at the 
Women's Hospital, Helsinki University Hospital (HUH) between January and April 2012. 
The My5000 series included 125 leiomyomas from 18 patients operated on at Jorvi Hospital 
(part of HUH) between March and June 2013. In the My5000 series, some tumor samples 
that served as routine diagnostic specimens were lost to the study. For the My1000 and 
My5000 series, the uteri were carefully scrutinized and all visible tumor nodules were 
collected, with the exception of one patient (My5013) who had > 20 leiomyomas, of which 
14 were obtained. For the My5000 series, the size of each tumor was recorded when 
possible; the smallest being 5 mm in diameter. The first 14 patients in the My5000 series, 
with a total of 103 leiomyomas, formed “the consecutive set”, whereas the My1000 series 
and the remaining samples from the My5000 series constituted “the unselected set” of 15 
patients with a total of 76 leiomyomas. Clinical data were collected from the patients’ 
medical records. 
For Study III, we collected a large well-documented series (My6000) of 763 leiomyomas 
from 244 patients, who underwent hysterectomy at the Kätilöopisto Maternity Hospital (part 
of HUH) between October 2013 and November 2015 (Table 5). Pathologists dissected the 
uteri, harvested all feasible leiomyomas > 10 mm in diameter, and recorded the size, 
location, and any special characteristics of the tumors. A formalin-fixed paraffin-embedded 
tissue block was prepared from each tumor. Pathological evaluation was based on the 
diagnostic pathology reports and all leiomyomas that were suspected to be histopathological 
variants were re-evaluated from hematoxylin-eosin-stained tissue slides by an expert 
gynecological pathologist. Clinical data were collected from the patients’ medical records 
and some of the patients completed a designed questionnaire.  
In Study IV, we selected 25 leiomyoma samples, obtained from 17 patients, based on their 
genetic driver determined in Studies II-III or during our previous efforts: seven leiomyomas 
were FH deficient, seven harbored a mutation in MED12, two displayed HMGA2 
overexpression, and nine were negative for all three, “the triple wild-type leiomyomas” 
(Table 5) (Mäkinen et al., 2011; Kämpjärvi et al., 2016b; Mehine et al., 2016). All tissue 
samples had been screened for MED12 mutations using Sanger sequencing and for 
chromosomal alterations using whole-genome sequencing or single-nucleotide 
polymorphism array data. Tumor samples with a deletion affecting the FH locus and the 
corresponding normal myometrium samples had been screened for FH mutations using 
Sanger sequencing. For tumor samples with chromosomal alterations affecting the HMGA2 
locus, the relative quantification of HMGA2 expression had been assessed using gene 
expression array data or HMGA2 quantitative polymerase chain reaction (qPCR). 
3. Mutation screening (I-IV) 
The FastDNA® Kit (MP Biomedicals LLC, Solon, OH, USA) was used to extract genomic 
DNA from fresh frozen tissue. Oligonucleotide primers were designed using Primer3 with 
the GRCh37/hg19 genome serving as a reference (Untergasser et al., 2012). Polymerase 




chain reaction (PCR) followed a standard protocol, and ExoSAP-IT (USB Corporation, 
Cleveland, OH, USA) or A’SAP (ArcticZymes, Tromsø, Norway) was used to purify the 
PCR products. Sequencing was performed with the Big Dye Terminator v.3.1 Kit (Applied 
Biosystems, Foster City, CA, USA) on an ABI3730 Automatic DNA Sequencer (Thermo 
Scientific Inc., Waltham, MA, USA) at the Technology Center, Institute for Molecular 
Medicine Finland, Helsinki, Finland. Sequence graphs were analyzed manually and with 
Mutation Surveyor software (Softgenetics, State College, PA, USA). 
4. HMGA2 qPCR (IV) 
Total RNA was extracted using NucleoZOL reagent (Macherey-Nagel GmbH & Co. KG, 
Germany). HMGA2 qPCR was performed on a 7500 Fast Real-Time PCR System with 
Assay No. Hs04397751_m1 (Applied Biosystems), using 18S rRNA as an endogenous 
control. Gene expression levels were assessed using the comparative Ct method. 
5. Gene expression data (IV) 
Previously generated and analyzed gene expression data using GeneChip Human Exon 1.0 
ST arrays (Affymetrix, Santa Clara, CA, USA) of 94 leiomyomas, including 10 with FH 
deficiency, 34 with a MED12 mutation, 27 with an HMGA2 rearrangement, and 23 triple 
wild-type leiomyomas, and of 60 corresponding myometrium samples were available for 
Study IV (Mehine et al., 2016). 
6. Metabolomic profiling (IV) 
Metabolon Inc. (Durham, NC, USA) performed the metabolomic profiling. Samples were 
prepared using the automated MicroLab STAR® system (Hamilton Company, Reno, NV, 
USA). For quality control (QC), recovery standards were added prior to extraction. A pooled 
matrix of study samples served as a technical replicate, water samples served as process 
blanks, and QC standards added to every sample allowed instrument performance 
monitoring and aided chromatographic alignment. 
The sample extract was dried then reconstituted in solvents compatible to each of the four 
independent platforms: two for analysis by two separate reverse phase ultra-performance 
liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS) methods with positive 
ion mode electrospray ionization (ESI), one for analysis by reverse phase UPLC-MS/MS 
with negative ion mode ESI, and one for analysis by hydrophilic interaction 
chromatography UPLC-MS/MS with negative ion mode ESI. All methods utilized an 
ACQUITY UPLC (Waters, Milford, MA, USA) and a Thermo Scientific Q-Exactive high 
resolution/accurate mass spectrometer interfaced with a heated ESI-II source and Orbitrap 
mass analyzer operated at 35 000 mass resolution. The first aliquot was analyzed using 
acidic positive ion conditions, chromatographically optimized for more hydrophilic 
compounds. In this method, the extract was gradient eluted from a C18 column (Waters 
UPLC BEH C18-2.1x100 mm, 1.7 μm) using water and methanol, containing 0.05% 
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perfluoropentanoic acid and 0.1% formic acid. The second aliquot was analyzed using 
acidic positive ion conditions using chromatographical optimization for more hydrophobic 
compounds. In this method, the extract was gradient eluted from the same C18 column using 
methanol, acetonitrile, water, 0.05% perfluoropentanoic acid, and 0.01% formic acid. The 
third aliquot was analyzed using basic negative ion optimized conditions using a separate 
C18 column. The basic extracts were gradient eluted from the column using methanol and 
water with 6.5mM ammonium bicarbonate at pH 8. The fourth aliquot was analyzed via 
negative ionization following elution from a hydrophilic interaction chromatography 
column (Waters UPLC BEH Amide 2.1x150 mm, 1.7 μm) using a gradient consisting of 
water and acetonitrile with 10mM ammonium formate at pH 10.8. The MS analysis 
alternated between MS and data-dependent MSn scans using dynamic exclusion. The scan 
range covered 70 to 1000 m/z. 
Raw data were extracted, peak-identified, and QC processed using Metabolon’s hardware 
and software. Compound identification was based on retention time/index, accurate mass 
match to the library +/- 10 ppm, and the MS/MS forward and reverse scores between the 
experimental data and authentic standards. The MS/MS scores are based on a comparison 
of the ions present in the experimental spectrum to the ions present in the Metabolon library 
spectrum containing >3300 purified standard compounds. Additional mass spectral entries 
were created for recurrent, structurally unnamed, biochemicals. The area under the curve 
was used to quantify the peaks. 
7. Statistical analyses (I-IV) 
In Study I, R software version 2.14.0 was used for statistical analyses (R Core Team, 2015). 
Pearson’s χ2 test was computed to assess the difference between the proportion of MED12-
mutation-positive leiomyomas in Finnish and South African patients. Fisher’s exact test was 
used to assess the difference between the frequency of large (> 5.5 cm in diameter, the mean 
tumor size in Finnish and South African patients) mutation-positive leiomyomas in South 
African and Finnish patients. A two-sided p-value (P) < 0.05 indicated statistical 
significance. 
In Study II, R software version 3.0.2 was used for statistical analyses (R Core Team, 2015). 
We used the Wilcoxon rank-sum test to assess the associations between MED12-mutation 
status and continuous clinical variables, including tumor size, number of leiomyomas, age 
at hysterectomy and diagnosis, diagnosis-to-hysterectomy interval, body mass index (BMI), 
uterine weight, parity, menarche, and alcohol consumption. We used Fisher's exact test to 
assess the associations between MED12-mutation status and nominal clinical variables, 
including nulliparity, cesarean section, miscarriage, infertility, menopausal status, smoking, 
reported symptoms, prior treatments, abnormal Papanicolaou smear, and other gynecologic 
diagnoses. A false-discovery rate correction was applied (Benjamini and Hochberg, 1995). 
A two-sided P < 0.05 denoted statistical significance. 
In Study III, R software version 3.2.3 was used for statistical analyses (R Core Team, 2015). 
To predict MED12-mutation status (a binary variable) by tumor characteristics (size, 
location, and histotype), we applied a generalized estimating equation method with an 




exchangeable correlation structure to take into account the possibility that multiple 
leiomyomas within a uterus may not be independent. We used Poisson regression to model 
MED12-mutation-negative-leiomyoma counts, and negative binomial regression to model 
MED12-mutation-positive-leiomyoma counts to account for overdispersion in the 
corresponding Poisson model. In both of these count models, explanatory variables included 
parity, menopausal status, age at hysterectomy, infertility, smoking, BMI, family history of 
leiomyomas, oral contraceptive use, history of chlamydia and pelvic inflammatory disease 
(PID), hypertension, thyroid disorder, diabetes, and prior leiomyoma surgery. We applied 
the likelihood ratio test, the generalized Pearson statistic, and model deviance to compare 
negative binomial and Poisson regression models and assess goodness of fit. Spearman 
correlation matrix and variance inflation factors were computed to evaluate possible 
collinearity among explanatory variables. We applied a Bonferroni correction (α = 0.05/34) 
to adjust for multiple comparisons; a two-sided P < 0.00147 indicated statistical 
significance. 
In Study IV, Partek Genomics Suite™ version 6.6 (Partek Inc., St. Louis, MO, USA) was 
used for statistical analyses. Raw metabolomic data were rescaled to set the median of each 
compound to 1 and were log2 transformed. Missing values were imputed with the minimum 
observed value for each compound. Principal component and unsupervised hierarchical 
clustering analyses (cosine dissimilarity) were performed for all samples using all 
metabolites. The correlation between tumor size (largest diameter) and the individual 
metabolite levels were evaluated using Pearson’s correlation coefficients. We used a two-
way analysis of variance (ANOVA) to identify metabolites that were dysregulated between 
leiomyomas and the corresponding myometrium samples. We used a one-way ANOVA to 
identify metabolites that were dysregulated in each leiomyoma subtype (FH, MED12, 
HMGA2, and triple wild type) as compared with all myometrium samples. We used three-
way ANOVA to compare leiomyomas of the MED12 and FH subtypes against the rest of 
the leiomyoma and myometrium samples to identify the most uniquely dysregulated 
metabolites. We employed pathway enrichment analysis using the significantly 
dysregulated metabolites for each leiomyoma subtype to identify significantly dysregulated 
pathways. False discovery rate correction was applied (Benjamini and Hochberg, 1995). A 
q-value < 0.1 denoted statistical significance. 
The gene expression data were analyzed previously by comparing leiomyomas of each 
subtype against all normal myometrium samples using one-way ANOVA followed by false 
discovery rate control (Mehine et al., 2016). We employed comparison analysis in Ingenuity 
Pathway Analysis version 33559992 (Qiagen, Redwood City, CA, USA) to identify 
pathways that were significantly dysregulated in both the metabolomic and gene expression 
data (P < 0.05 in both) for leiomyomas of the FH, MED12, and HMGA2 subtypes. Analysis 
was carried out with each set of significantly dysregulated metabolites (q-value < 0.1) and 





1. MED12 mutations in leiomyomas (I-III) 
1.1. MED12 mutations in different sample series (I-III) 
We detected MED12 exon 2 mutations in 14 (50%) out of 28 leiomyomas from 18 South 
African patients, including 6 Black African and 12 Colored women (Figure 4A). Nine (50%) 
patients had at least one mutation-positive tumor. All mutations were heterozygous and 
resulted in an in-frame transcript. Normal myometrium was available from 14 patients, and 
the somatic status of the mutations in leiomyomas from these patients (10/14, 71%) was 
confirmed.  
We detected MED12 exon 1 and 2 mutations in 73 (83%) out of 88 leiomyomas from 13 
consecutive patients (Figure 4B), in 65 (86%) out of 76 leiomyomas from 15 unselected 
patients (Figure 4C), and in 599 (79%) out of 763 leiomyomas from the My6000 series of 
244 patients (Figure 4D). Correspondingly, 10 (77%) out of 13 consecutive patients, 11 
(73%) out of 15 unselected patients, and 177 (73%) out of 244 patients had at least one 
MED12-mutation-positive leiomyoma. All mutations were heterozygous and somatic, and 
resulted in an in-frame transcript. Of note, one patient with 15 MED12-mutation-negative 
leiomyomas in the consecutive series was excluded from the analysis due to a germline FH 
mutation, because the objective was to study the frequency of MED12 mutations in sporadic 
leiomyomas. 
1.2. MED12-mutation status and clinical characteristics (I-III) 
The frequency of MED12 mutations was significantly different in leiomyomas from South 
African women as compared to leiomyomas from Finnish women in the MED12-mutation 
discovery study (P = 0.045), but no significant difference was found when only the large 
tumors were taken into consideration (P = 0.69) (Mäkinen et al., 2011). In the series of 244 
patients, 25 were of non-Finnish origin; the mutation frequencies were similar in 
leiomyomas from Finns (535/679, 79%) and from non-Finns (64/84, 76%). 
MED12-mutation-positive tumors were significantly smaller than mutation-negative tumors 
in the analysis of 108 leiomyomas in Study II (P = 0.026), as well as in the analysis of 748 
leiomyomas in Study III (P = 4.2×10−9), in which positive mutation status was also 
associated with conventional histology (P = 0.0013), and subserous relative to intramural 
location (P = 0.00082). 
In Study II, we explored the associations between MED12-mutation status and various 
clinical variables by comparing 21 patients having at least one mutation-positive leiomyoma 
with 7 patients having only mutation-negative leiomyomas. The patients with MED12- 
mutation-positive tumors had significantly more tumors than patients with only mutation-
negative leiomyomas (P = 0.010). We found no significant associations (P > 0.05) between 






Figure 4. The distribution of different types of MED12 mutations in the different sample series. The 
proportion of missense mutations affecting different codons, in-frame insertion and/or deletions (indel) 
affecting exon 1 - intron 1 and intron 1- exon 2, as well as wild-type lesions are shown separately. Codon 44 
(G44) mutations are presented in more detail. Panel D is adapted from Study III under Creative Commons 




hysterectomy interval, uterine weight, parity, cesarean section, miscarriage, infertility, 
menarche, menopausal status, alcohol consumption, smoking, reported symptoms, prior 
treatments, abnormal Papanicolaou smear, nor any other gynecologic diagnosis. A greater 
proportion of patients with mutation-positive tumors were nulliparous (12/29, 57%) than 
patients with only mutation-negative tumors (1/7, 14%), although the difference was non-
significant (P > 0.05). The patient who was excluded from the analyses due to a germline 
FH mutation was diagnosed at the youngest age, had a history of a prior myomectomy, and 
had a notable family history of leiomyomas. 
In the analysis of 244 patients in Study III, we observed a strong correlation between the 
number of MED12-mutation-positive tumors and the total number of leiomyomas 
(Spearman’s correlation coefficient 0.87, P = 1.3 × 10−77), but no correlation between the 
number of mutation-negative tumors and the total number of leiomyomas. We used separate 
regression models to study the association between the number of MED12-mutation-
positive and –negative leiomyomas and clinical factors that have previously been associated 
with the risk of developing leiomyomas; the number of mutation-positive tumors was 
inversely associated with parity (P = 0.00017) and the number of mutation-negative tumors 
was significantly associated with a history of PID (P = 0.00024). No associations were 
observed between the number of mutation-positive or -negative leiomyomas and age at 
hysterectomy, menopausal status, infertility, smoking, BMI, family history of leiomyomas, 
oral contraceptive use, history of chlamydia, hypertension, thyroid disorder, diabetes, nor 
prior leiomyoma surgery (P > 0.00147). 
2. Metabolomic profile of leiomyomas (IV) 
Metabolomic analysis identified a total of 588 named and 53 recurrent unnamed metabolites 
in 25 leiomyoma and 17 myometrium samples. The FH-deficient leiomyomas displayed a 
clearly distinct metabolomic profile according to the principal component and unsupervised 
hierarchical clustering analyses (Figure 5A-B). Tumor size correlated significantly with 
tryptophan betaine (r = 0.65, q-value = 0.082) and glucose (r = -0.64, q-value = 0.089) 
levels. 
A total of 70 metabolites were significantly differentially abundant in all leiomyomas when 
compared to the corresponding myometrium samples. The most significantly dysregulated 
metabolite was homocarnosine (Figure 5C). Leiomyomas of the FH, MED12, HMGA2, and 
triple wild-type subtypes displayed 170, 104, 35, and 22 significantly differentially 
abundant metabolites, respectively (Table 6). The majority of the significantly dysregulated 
metabolites were elevated in leiomyomas of the FH and HMGA2 subtypes, whereas the 
majority were reduced in the MED12 and triple wild-type subtypes. In the analysis of 
uniquely dysregulated metabolites that represent candidate biomarkers, the most significant 
metabolites in leiomyomas of the FH subtype were fumarate, N6-succinyladenosine, and 







Figure 5. Metabolomic profile of leiomyomas. FH-deficient leiomyomas clustered together in A) the 
unsupervised hierarchical clustering analysis and B) the principal component analysis (PCA). C) 
Homocarnosine was the most significantly dysregulated metabolite when all leiomyomas were compared with 
the corresponding myometrium samples. Red denotes leiomyomas with FH deficiency, blue with HMGA2 
overexpression, and green with a MED12 mutation, grey denotes normal myometrium samples and orange 




Table 6. The ten most significantly dysregulated metabolites in leiomyomas of FH, MED12, HMGA2, and 
triple wild type subtypes. 
Metabolite Pathway Q-value Fold change 
FH    
N6-succinyladenosine Purine metabolism, adenine containing 8.3x10-11 193.7 
Fumarate Tricarboxylic acid cycle 8.3x10-11 12.0 
Argininosuccinate Urea cycle; arginine and proline metabolism 9.6x10-11 38.5 
Malate Tricarboxylic acid cycle 1.5x10-9 10.5 
3-methyl-2-oxobutyrate Leucine, isoleucine, and valine metabolism 4.4x10-9 8.3 
X - 24728 Unnamed 6.1x10-9 231.1 
Maleate Fatty acid, dicarboxylate 2.2x10-8 18.3 
4-methyl-2-oxopentanoate Leucine, isoleucine, and valine metabolism 7.2x10-7 6.5 
X - 15150 Unnamed 1.4x10-6 -8.8 
β-citrylglutamate Glutamate metabolism 1.4x10-6 -5.8 
MED12    
Homocarnosine Dipeptide derivative 5.5x10-6 -18.8 
Phenylalanine Phenylalanine metabolism 5.5x10-6 -2.2 
Histamine Histidine metabolism 1.3x10-5 -35.9 
Biliverdin Hemoglobin and porphyrin metabolism 1.3x10-5 -5.1 
Tyrosine Tyrosine metabolism 1.3x10-5 -2.0 
X - 21796 Unnamed 1.4x10-5 -7.5 
X - 15150 Unnamed 2.2x10-5 -7.4 
X - 12206 Unnamed 5.3x10-5 -4.7 
Leucine Leucine, isoleucine, and valine metabolism 0.00051 -1.5 
N-acetyl-aspartyl-glutamate Glutamate metabolism 0.00068 9.1 
HMGA2    
3-hydroxydecanoate Fatty acid, monohydroxy 0.00038 9.4 
Behenoyl dihydrosphingomyelin (d18:0/22:0)* Sphingolipid metabolism 0.00039 -5.6 
X - 24243 Unnamed 0.00039 3.5 
Palmitoyl dihydrosphingomyelin (d18:0/16:0)* Sphingolipid metabolism 0.00091 -4.1 
1-(1-enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4)* Plasmalogen 0.0028 -1.8 
Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2]* Diacylglycerol 0.0029 5.8 
Sphingomyelin (d18:0/18:0, d19:0/17:0)* Sphingolipid metabolism 0.0041 -5.5 
Oleoyl-linoleoyl-glycerol (18:1/18:2) [2] Diacylglycerol 0.0041 2.8 
Heme Hemoglobin and porphyrin metabolism 0.0044 -12.6 
Isobutyrylcarnitine (C4) Leucine, isoleucine, and valine metabolism 0.0052 -8.1 
Triple wild type    
Homocarnosine Dipeptide derivative 3.8x10-5 -12.7 
Phenylpyruvate Phenylalanine metabolism 0.00022 -2.7 
Heme Hemoglobin and porphyrin metabolism 0.0015 -3.9 
Biliverdin Hemoglobin and porphyrin metabolism 0.0015 -3.2 
X - 21796 Unnamed 0.0043 -3.4 
Threonate Ascorbate and aldarate metabolism 0.0051 -3.0 
Retinol (Vitamin A) Vitamin A metabolism 0.0054 -1.8 
Dehydroascorbate Ascorbate and aldarate metabolism 0.0086 -2.2 
Isobutyrylcarnitine (C4) Leucine, isoleucine, and valine metabolism 0.012 -3.4 







Pathway enrichment analysis using the metabolomic data predicted multiple pathways to be 
significantly dysregulated in each leiomyoma subtype (Table 7). Ingenuity pathway analysis 
comparing the metabolomic and gene expression data revealed six significantly 
dysregulated pathways in the FH subtype: Pentose Phosphate Pathway, Pentose Phosphate 
Pathway (Oxidative Branch), tRNA Splicing, Gluconeogenesis I, IL-10 Signaling, and 
Salvage Pathways of Pyrimidine Ribonucleotides; two significantly dysregulated pathways 
in the MED12 subtype: Antioxidant Action of Vitamin C and Type II Diabetes Mellitus 
Signaling; and two significantly dysregulated pathways in the HMGA2 subtype: Putrescine 
Degradation III and Sphingosine-1-phosphate Signaling. 
Table 7. Significantly enriched pathways predicted from metabolomic data for leiomyomas of FH, MED12, 
HMGA2, and triple wild type subtypes.     
















FH      
Plasmalogen 5.4 0.0047 6 | 1 10 70 
Glycogen metabolism 5.3 0.0048 4 | 0 4 100 
Tricarboxylic acid cycle 5.1 0.0059 5 | 0 6 83 
Sphingolipid metabolism 4.6 0.0096 7 | 10 38 45 
Pentose phosphate pathway 4.0 0.018 0 | 3 3 100 
Diacylglycerol 3.3 0.036 8 | 0 16 50 
MED12      
Sphingolipid metabolism 22.6 1.5x10-10 0 | 23 38 61 
Phosphatidylserine 5.5 0.0042 0 | 3 3 100 
Ascorbate (vitamin C) and aldarate metabolism 4.2 0.015 0 | 3 4 75 
Dipeptide 3.2 0.043 0 | 4 9 44 
Methionine, cysteine, S-adenosylmethionine, 
and taurine metabolism 3.1 0.044 1 | 4 13 38 
HMGA2      
Plasmalogen 9.5 7.5x10-5 4 | 1 10 50 
Sphingolipid metabolism 7.6 0.00053 1 | 7 38 21 
Diacylglycerol 4.8 0.0085 4 | 0 16 25 
Fatty acid, monohydroxy 3.6 0.026 2 | 0 5 40 
Triple wild type      
Hemoglobin and porphyrin metabolism 5.0 0.0065 0 | 2 4 50 
Ascorbate (vitamin C) and aldarate metabolism 5.0 0.0065 0 | 2 4 50 
Vitamin A metabolism 3.4 0.034 0 | 1 1 100 





1. MED12 mutations in tumorigenesis 
1.1. MED12 mutations in leiomyomas and other neoplasms 
The breakthrough discovery of MED12 mutations in the majority of leiomyomas suggested 
that MED12 plays an important role in leiomyomagenesis (Mäkinen et al., 2011). Since the 
initial finding, this thesis and multiple other studies with various sample sizes encompassing 
patients of diverse racial and ethnic origins have validated the occurrence of these mutations 
in leiomyomas (Table 8). The reported frequencies of MED12 mutations have ranged from 
31 to 92%. This large variance in mutation frequencies is probably attributable to small 
sample sizes and bias introduced by tumor size rather than the ethnicity of the patients. This 
thesis demonstrated that when the smaller leiomyomas are also examined, the mutation 
frequency is as high as 86%, and in the largest leiomyoma series thus far with carefully 
controlled size bias, the mutation frequency was 79%. Recently, we detected that a small 
proportion of leiomyomas, including one leiomyoma from the South African series, harbor 
mutations at the end of MED12 exon 1 (Kämpjärvi et al., 2014). Exon 1 mutations were not 
covered in MED12-mutation-screening studies by others; however, these mutations explain 
only a small proportion of the variance in the mutation frequencies. Despite the large 
variance in the frequencies of MED12 mutations, their spectrum has been consistent across 
all mutation-screening studies, with the vast majority of the mutations affecting the highly 
conserved codon 44. 
As also demonstrated in this thesis, MED12-hotspot mutations occur in leiomyoma variants, 
but with notably lower frequencies than in conventional leiomyomas (Table 9). Moreover, 
up to 30% of malignant leiomyosarcomas harbor these mutations. Leiomyoma variants and 
leiomyosarcomas are typically driven by other genetic aberrations than MED12 mutations, 
including FH, HMGA2, tumor protein P53 (TP53), RB transcriptional corepressor 1 (RB1), 
and ATRX, chromatin remodeler (ATRX) mutations (Sandberg, 2005b; Zhang et al., 2014; 
Liegl-Atzwanger et al., 2016; Mäkinen et al., 2016; 2017). In addition, most 
leiomyosarcomas display aneuploidy and structural chromosomal alterations (Sandberg, 
2005b). The presence of MED12 mutations in a subset of leiomyosarcomas indicates that a 
benign leiomyoma, or more plausibly a leiomyoma variant, may gain additional mutations 
transforming it into a malignant leiomyosarcoma. Further affirming the possibility of 
malignant transformation, leiomyosarcomas with morphologically benign areas, which 
often resemble leiomyomas with bizarre nuclei or high cellularity, display identical MED12 
mutations in both, the benign and malignant, components (Mittal et al., 2009; Matsubara et 
al., 2013). Considering the large difference in the incidences of these two tumor types, 
malignant transformation would occur on rare occasions. In leiomyosarcomas, MED12 
mutations may represent merely passenger mutations or secondary mutations providing a 
growth advantage to malignant cells. Furthermore, the role of mutated MED12 in 
malignancy seems unlikely since the majority of leiomyosarcomas display reduced protein 





Table 8. Summary of the studies reporting MED12 mutations in leiomyomas. 















Finnish 1% (4/225) 71% (159/225) 3.7 75% (60/80) 80 (Mäkinen et al., 2011; Kämpjärvi et al., 2014) 
Finnish 0% (0/71) 61% (43/71) NA NA NA (Mäkinen et al., 2013; 2017; Kämpjärvi et al., 2016b) 
Finnish/Romanian 0% (0/88) 83% (73/88) 3.5 77% (10/13) 13 Study II 
Finnish/Swedish 1% (1/76) 85% (64/76) 2.8 73% (11/15) 15 Study II 
Finland 1% (6/763) 79% (599/763) 3.8 73% (177/244) 244 Study III 
Finns 1% (6/679) 79% (535/679) 3.7 73% (160/219) 219  
non-Finns 0% (0/84) 76% (64/84) 4.7 68% (17/25) 25  
Russian NA 73% (11/15) NA 73% (11/15) 15 (Osinovskaya et al., 2013) 
Russian NA 52% (63/122) NA NA 76 (Osinovskaya et al., 2015) 
German NA 59% (47/80) 5.3 NA 50 (Markowski et al., 2012) 
German NA 48% (10/21) NA 48% (10/21) 21 (Markowski et al., 2013) 
German NA 92% (11/12) NA 100% (2/2) 2 (Rieker et al., 2013) 
German NA 70% (179/256) NA NA NA (Markowski et al., 2014a) 
Dutch NA 58% (11/19) 6.5 56% (9/16) 16 (de Graaff et al., 2013) 
French NA 67% (6/9) NA 67% (6/9) 9 (Perot et al., 2012) 
American/ 
Austrian/French NA 61% (11/18) 5.0 58% (8/14) 12 
(Liegl-Atzwanger et al., 
2016) 
Mixed American NA 68% (100/148) 5.5 68% (100/148) 148 (McGuire et al., 2012) 
Black NA 78% (18/23) 6.1 78% (18/23) 23  
White NA 66% (79/120) 5.4 66% (79/120) 120  
Mixed American NA 75% (133/178) 11.9 NA 134 (Bertsch et al., 2014) 
Asian NA 67% (4/6) NA NA 4  
Black NA 79% (64/81) NA NA 64  
Hispanic NA 81% (13/16) NA NA 13  
White NA 72% (53/74) NA NA 52  
Mixed American NA 64% (92/143) NA 62% (84/135) 135 (Halder et al., 2015) 
Black NA NA NA 66% (45/68) 68  
Hispanic NA NA NA 60% (26/43) 24  
White NA NA NA 54% (13/24) 43  
American NA 69% (9/13) NA NA NA (Ravegnini et al., 2013) 
American NA 54% (15/28) NA 54% (15/28) 28 (Schwetye et al., 2014) 
American/Chinese NA 75% (30/40) NA 75% (30/40) 40 (Zhang et al., 2014) 
Chinese NA 52% (95/181) NA 52% (95/181) 181 (Wang et al., 2015) 
Japanese NA 80% (36/45) NA NA NA (Matsubara et al., 2013) 
Korean NA 52% (35/67) 6.1 52% (35/67) 67 (Je et al., 2012) 
Iranian NA 48% (11/23) NA 48% (11/23) 23 (Shahbazi et al., 2015) 
Iranian NA 31% (32/103) 5.3 NA 58 (Sadeghi et al., 2016) 






Table 9. Frequency of MED12 mutations in uterine smooth muscle tumors. 
Histopathological subtype Frequency Reference(s) 
Cellular leiomyoma 33% (2/6) (Matsubara et al., 2013) 
 9% (6/69) (Mäkinen et al., 2013; 2017) 
 14% (3/22) (Zhang et al., 2014) 
 0% (0/1) (Liegl-Atzwanger et al., 2016) 
 44% (7/16) Study III 
Epithelioid leiomyoma 100% (1/1) Study III 
Intravenous leiomyomatosis 0% (0/9) (Buza et al., 2014) 
Leiomyoma with bizarre nuclei 25% (1/4) (Matsubara et al., 2013) 
 16% (3/19) (Mäkinen et al., 2013; 2017) 
 10% (4/42) (Zhang et al., 2014) 
 10% (1/10) (Liegl-Atzwanger et al., 2016) 
 50% (1/2) Study III 
Lipoleiomyoma 0% (0/4) (Matsubara et al., 2013) 
 0% (0/3) Study III 
Mitotically active leiomyoma 38% (10/26) (Mäkinen et al., 2013) 
 86% (6/7) (Zhang et al., 2014) 
 75% (3/4) Study III 
Smooth muscle tumor of uncertain malignant potential 11% (1/9) (Perot et al., 2012) 
 8% (1/12) (Schwetye et al., 2014) 
 11% (2/18) (Zhang et al., 2014) 
Uterine leiomyosarcoma 0% (0/5) (Je et al., 2012) 
 7% (3/41) (Kämpjärvi et al., 2012)  
 20% (2/10) (Perot et al., 2012) 
 14% (1/7) (de Graaff et al., 2013) 
 7% (1/14) (Markowski et al., 2013) 
 17% (2/12) (Matsubara et al., 2013) 
 20% (3/15) (Ravegnini et al., 2013) 
 9% (3/32) (Bertsch et al., 2014) 
 30% (6/20) (Schwetye et al., 2014) 
 11% (4/38) (Zhang et al., 2014) 
 4% (1/24) (Wang et al., 2015) 
 25% (2/8) (Liegl-Atzwanger et al., 2016) 
 22% (11/51) (Mäkinen et al., 2016; 2017) 
 5% (7/153) (Yatsenko et al., 2017) 
 
MED12-hotspot mutations occur also in extrauterine smooth muscle tumors: disseminated 
peritoneal leiomyomatosis (7/7, 100%), extrauterine leiomyomas (15/192, 8%), one 
extrauterine leiomyosarcoma (1/136, 1%), and genital leiomyomas in dogs (2/10, 20%) 
(Kämpjärvi et al., 2012; Perot et al., 2012; de Graaff et al., 2013; Markowski et al., 2013; 
Matsubara et al., 2013; Ravegnini et al., 2013; Rieker et al., 2013; Schwetye et al., 2014). 
In other benign tumor types, MED12-hotspot mutations have been observed with notable 
frequencies in fibroadenomas (47 to 86%) and phyllodes tumors (45 to 80%) of the breast 
(Lim et al., 2014; Cani et al., 2015; Mishima et al., 2015; Nagasawa et al., 2015; Tan et al., 
2015; Yoshida et al., 2015). In malignant neoplasms, hotspot mutations are frequent in 
uterine adenosarcomas (11%) and chronic lymphocytic leukemia (5%), but only few 
mutations have been found in other cancer types (Je et al., 2012; Kämpjärvi et al., 2012; 
2015; Yuan et al., 2017). Mutations slightly further down exon 2 of MED12, affecting 
amino acids Q48 and D54, have emerged in 3 out of 14 (21%) endometrial stromal 
sarcomas, but the role of these mutations in pathogenesis is unclear (Yuan et al., 2017). 





prostate cancer, adrenocortical carcinomas, endometrioid endometrial carcinomas, and 
renal cell cancer; these mutations are likely to promote tumorigenesis through distinct 
mechanisms in comparison to leiomyoma-hotspot mutations (Barbieri et al., 2012; Arai et 
al., 2014; Assié et al., 2014; Kämpjärvi et al., 2016a; Uterine Corpus Endometrioid 
Carcinoma, TCGA, USA, import from ICGC: COSU419). 
In summary, MED12 mutations are frequent in benign female-steroid-hormone-dependent 
tumors of mesenchymal-stem-cell origin, suggesting that MED12 plays a role in the benign 
tumorigenesis of the mesenchymal cell lineage under hormonal control. Although MED12 
mutations occur also in malignant neoplasms, their role and timing in tumor evolution and 
malignancy remain obscure. 
1.2. MED12 mutations and clinical features 
Our results confirmed the prior notion that smaller tumor size is associated with positive 
MED12-mutation status, a finding supported by multiple reports, although a few studies 
with small sample sizes failed to detect a significant association (Mäkinen et al., 2011; Je 
et al., 2012; Markowski et al., 2012; de Graaff et al., 2013; Bertsch et al., 2014; 
Osinovskaya et al., 2015; Ye et al., 2015). In addition, this thesis showed that patients with 
MED12-mutation-positive leiomyomas tend to have multiple concurrent lesions, which is 
supported by findings of other studies (McGuire et al., 2012; Markowski et al., 2014a; 
Osinovskaya et al., 2015). The multiplicity of tumors may contribute to the smaller size of 
MED12-mutation-positive leiomyomas, as multiple tumors are likely to manifest clinically 
earlier than solitary tumors. Otherwise, other genetic drivers, such as HMGA2, may induce 
more potent growth-promoting changes than MED12 mutations (Markowski et al., 2012). 
Patients having multiple synchronous leiomyomas, typically harboring non-identical 
MED12 mutations, may be explained by genetic predisposition, epigenetic alterations, or 
exposure to external factors, such as steroid hormones, rendering the myometrium prone to 
MED12 mutations. Approximately a quarter of the patients have only mutation-negative 
leiomyomas; these patients are likely to harbor leiomyomas driven by, for example, HMGA2 
aberrations (Markowski et al., 2014a). Comparing the genetic, epigenetic, and clinical 
features between patients having numerous MED12-mutation-positive leiomyomas and 
patients having solely mutation-negative lesions could enlighten the mechanisms 
underlying the predisposition for mutation-positive tumors. 
This thesis revealed that subserosal leiomyomas tend to be MED12-mutation positive. Two 
other studies found no significant association between the mutation status and leiomyoma 
location, possibly due to smaller sample sets (Je et al., 2012; Osinovskaya et al., 2015). 
Nonetheless, our finding together with the previous notion that submucosal leiomyomas 
display significantly fewer clonal cytogenetic changes compared to other types suggests that 
differences in the structurally and functionally distinct myometrial layers influence the 
molecular mechanisms leading to leiomyoma development (Brosens et al., 1998; Noe et al., 
1999). As the range of symptoms caused by leiomyomas depends on the number, location, 
and size of the tumors, the established differences in these features between MED12-
mutation-positive and -negative leiomyomas suggest that these tumors are likely to manifest 




This thesis discovered that the number of MED12-mutation-positive leiomyomas decreases 
with increasing parity. Another study found no difference between the parity of patients 
with only one leiomyoma with HMGA2 translocation and patients with at least one MED12-
mutation-positive tumor (Markowski et al., 2014a). Increasing parity and more recent 
pregnancies are known to reduce the risk of leiomyomas, but the underlying mechanism is 
unclear (Ross et al., 1986; Parazzini et al., 1988; 1996; Lumbiganon et al., 1996; Marshall 
et al., 1998; Sato et al., 2002; Wise et al., 2004a; Parazzini, 2006; Terry et al., 2010; Uimari 
et al., 2016). Possibly, post-pregnancy remodeling of the uterus induces leiomyoma 
regression and eliminates smaller lesions, which are typically MED12-mutation positive 
(Baird and Dunson, 2003; Laughlin et al., 2010). Alternatively, the hormonal changes 
during and after pregnancy may affect mutation-positive and -negative leiomyomas 
differently, as many, but not all, leiomyomas shrink during pregnancy (Laughlin et al., 
2010). 
Our analysis revealed a significant association between increasing number of MED12-
mutation-negative tumors and a history of PID, suggesting that either inflammatory stimuli 
or a tumorigenic infectious agent may induce the development of mutation-negative 
leiomyomas. This view is supported by epidemiological studies: reproductive tract 
infections increase the risk of leiomyomas, whereas a history of PID showed a trend towards 
an inverse association with the number of tumors (Faerstein et al., 2001b; Moore et al., 
2015). If inflammation or infectious agents give rise to some leiomyomas, these tumors 
could perhaps be prevented with an appropriate treatment or a vaccine. 
We found one patient to be a carrier of a germline FH mutation. This patient had 15 MED12-
mutation-negative leiomyomas, was young at the time of diagnosis (30 years old), had a 
history of a prior myomectomy, and had a prominent family history of leiomyomas. This 
patient case highlights the clinical features of HLRCC-related leiomyomas, which include 
early age of onset, familial aggregation, and multiplicity of tumors that, when encountered 
in the clinic, should raise the suspicion of an underlying hereditary syndrome so that 
appropriate counseling and follow-up can be arranged (Lehtonen, 2011; Tolvanen et al., 
2012). To facilitate screening for FH deficiency in patients presenting with these clinical 
features, establishing robust non-invasive biomarkers is vital. 
Taken together, these differences in the characteristics and predisposing factors of MED12-
mutation-positive and –negative leiomyomas highlight the diversity of the molecular 
mechanisms leading to the development of these tumors. The genetic defects underlying 
leiomyomas may be triggered and affected by different factors, such as inflammation and 
hormones, and may partly account for the heterogeneity in the clinical presentation, growth 
pattern, and drug responses of leiomyomas. 
1.3. Tumorigenic mechanism of MED12 mutations 
In addition to the high frequency of MED12 mutations, the presence of these mutations in 
leiomyoma stem cells suggests that MED12 mutations drive leiomyomagenesis (Ono et al., 
2012). Recent studies on leiomyomas have shown that MED12 mutations, FH inactivation, 
and HMGA2 aberrations are mutually exclusive genetic events that result in distinct gene 





Mehine et al., 2016; Mäkinen et al., 2017). Furthermore, a MED12 mutation alone seems 
to be sufficient for tumor formation, as no other concurrent recurrent small-scale mutations 
have been detected in MED12-mutation-positive leiomyomas, and many of the 
chromosomal aberrations that co-occur with MED12 mutations, such as 7q deletions, 
typically exist as subclonal changes indicating that they represent secondary events with a 
tumor-promoting role (Markowski et al., 2012; Mäkinen et al., 2014b). 
The mutation pattern strongly suggests that MED12 mutations are of a gain-of-function type 
and that mutated MED12 acts as an oncogene. Functional studies revealed that MED12-
hotspot mutations disrupt the binding interface between MED12 and Cyclin C resulting in 
diminished CDK8-kinase activity (Kämpjärvi et al., 2014; Turunen et al., 2014). 
Leiomyomas harbor no recurrent mutations in any of the other components of the CDK8 
module further highlighting the specific functional effect of MED12 mutations (Mäkinen et 
al., 2014a). These mutations may promote tumorigenesis through altered Wnt/β-catenin 
signaling, although the data are contradictory: our recent gene expression data indicated 
inhibition of the Wnt/β-catenin pathway in leiomyomas, whereas many studies have 
suggested that the activation of this pathway plays a role in leiomyomagenesis (Mäkinen et 
al., 2011; Markowski et al., 2012; Perot et al., 2012; de Graaff et al., 2013; Ono et al., 2013; 
2014; Mehine et al., 2016; Al-Hendy et al., 2017). MED12-mutation-positive tumors show 
dysregulation of extracellular matrix genes implying that MED12 may also affect 
extracellular matrix remodeling (Lim et al., 2014; Mehine et al., 2016; Al-Hendy et al., 
2017). In addition, MED12 mutations may contribute to tumorigenesis by altering the cells’ 
sensitivity to steroid hormones, as MED12 regulates steroid-hormone receptors and 
MED12-mutation-positive breast fibroadenomas display activation of estrogen signaling 
(Prenzel et al., 2012; Lim et al., 2014; Al-Hendy et al., 2017). Intriguingly, a non-coding 
transcript of RAD51B, the preferred translocation partner of HMGA2, is the most 
significantly dysregulated gene in MED12-mutation-positive leiomyomas (Mehine et al., 
2016). The tumorigenic mechanism of MED12 mutations requires further studies, which 
have been hampered due to the challenges encountered in establishing a leiomyoma cell line 
carrying a MED12 mutation (Markowski et al., 2014b). On a positive note, a recently 
engineered mouse model, which conditionally expresses the most frequent hotspot mutation 
in uterine mesenchymal cells and consequently develops leiomyoma-like lesions in the 
uterus, provides a platform for studying MED12-driven tumorigenesis (Mittal et al., 2015). 
Aside from MED12 mutations, next-generation sequencing studies have identified no other 
genes that harbor recurrent somatic point mutations in leiomyomas (Mäkinen et al., 2011; 
2014b; McGuire et al., 2012; Mehine et al., 2013). On the contrary, whole-genome 
sequencing revealed interconnected complex chromosomal rearrangements in mostly 
MED12-mutation-negative leiomyomas (Mehine et al., 2013). These rearrangements 
resembled a milder form of an event previously observed in cancers called chromotripsis, 
in which chromosomes shatter into pieces and randomly reassemble (Stephens et al., 2011). 
Some of these complex chromosomal rearrangements had formed aberrations characteristic 
for leiomyomas, such as HMGA2-RAD51B translocations (Mehine et al., 2013). In addition, 
a whole-genome sequencing and subsequent validation study showed that multiple separate 




Taken together, next-generation sequencing technologies have revolutionized our 
understanding of leiomyomas: instead of a single homogeneous group of tumors, they 
comprise multiple distinct molecular subtypes that seem to arise and behave differently, and 
perhaps should be managed with different treatments. The established molecular subtypes 
include leiomyomas driven by MED12 mutations, HMGA2 overexpression, and FH 
deficiency. Together these drivers account for the great majority of leiomyomas, leaving 
only a fraction of them without an identified initiator. Putative driver genes affected by a 
sole chromosomal alteration in leiomyomas include high mobility group AT-hook 1 
(HMGA1), collagen type IV α 5 chain and 6 chain (COL4A5 and COL4A6), and lysine 
acetyltransferase 6B (KAT6B), but due to the rarity of these aberrations, more samples are 
required to establish their potential initiating role (Moore et al., 2004; Nezhad et al., 2010; 
Mehine et al., 2013). Although the main drivers of leiomyomagenesis have now been 
identified, their tumor-driving molecular mechanisms remain largely elusive. 
2. Metabolomic alterations in leiomyomas 
As a first study of its kind, we explored the global metabolomic profiles of leiomyomas 
representing the three main molecular subtypes classified according to their mutually 
exclusive driver changes: MED12 mutations, FH inactivation, and HMGA2 aberrations 
(Markowski et al., 2012; Bertsch et al., 2014; Kämpjärvi et al., 2016b; Mäkinen et al., 
2017). We discovered that these genetic triggers lead to differences in the metabolomic 
profiles of leiomyomas: the FH-deficient leiomyomas represented a metabolically distinct 
subtype that can be distinguished from other leiomyomas and the myometrium samples 
based on their metabolomic profile. We identified multiple dysregulated metabolites in the 
different molecular subtypes of leiomyomas, which may contribute to their development in 
multiple ways, such as by providing energy and building blocks, acting as antioxidants, or 
by regulating signaling pathways involved in proliferation and differentiation. Moreover, 
some of the dysregulated metabolites may prove to be useful biomarkers or targets for 
prevention and treatment of leiomyomas. 
All leiomyomas displayed significant reduction of the antioxidant homocarnosine, the 
important cofactor heme, and its degradation product biliverdin indicating that alterations 
in the metabolic pathways of these compounds are characteristic for all leiomyomas (Kohen 
et al., 1988). How these alterations arise and affect leiomyoma development is unclear, and 
thus their further scrutiny could uncover similarities in the tumor-driving mechanisms of 
the different genetic drivers that could be targeted to treat all leiomyomas. 
2.1. Metabolomic alterations in MED12-mutation-positive leiomyomas 
In MED12-mutation-positive leiomyomas, the significant changes in the metabolite levels 
were mainly decreases, possibly reflecting limited supply of building blocks that may 
contribute to the smaller size of these leiomyomas. Among the reduced metabolites were 
various amino acids, their derivatives, and dipeptides, which may indicate enhanced protein 
synthesis in these leiomyomas. In addition, dysregulated methionine, cysteine, S-





and DNA, as S-adenosylmethionine is a coenzyme in methyl-group transfer reactions 
(Teperino et al., 2010). MED12-mutation-positive leiomyomas displayed also reduced 
levels of sphingolipids and phosphatidylserines, which are components of the cell 
membrane and play a role in various signaling pathways (Ogretmen and Hannun, 2004; 
Vance and Steenbergen, 2005). 
One of the reduced metabolites in MED12-mutation-positive leiomyomas was RA precursor 
retinol (vitamin A). Prior studies have suggested that RA inhibits proliferation, induces 
apoptosis, and reduces expression of ECM components in leiomyoma cells (Broaddus et al., 
2004; Gilden et al., 2012; Borahay et al., 2015; Stewart et al., 2016). In epidemiological 
studies, higher serum concentration of vitamin A was associated with increased risk of 
leiomyomas, whereas dietary vitamin A intake was associated with reduced risk (Martin et 
al., 2011; Wise et al., 2011). Based on gene expression data, RA receptor activation is one 
of the most significantly dysregulated pathways in leiomyomas (Mehine et al., 2016). 
Importantly, drugs increasing RA levels have been well tolerated in clinical studies 
(Debruyne et al., 1998; Camerini et al., 2001). Hence, targeting RA metabolism should be 
further explored as a putative therapy and prevention mechanism for leiomyomas, and in 
particular, for MED12-mutation-positive leiomyomas. 
MED12-mutation-positive leiomyomas displayed reduction of metabolites of ascorbate 
(vitamin C) together with the predicted activation of the antioxidant action of vitamin C 
pathway. In addition to its antioxidant activity, vitamin C contributes to other important 
cellular processes including collagen synthesis, DNA methylation, and nuclear factor κB 
mediated signaling (Cárcamo et al., 2004; Du et al., 2012; Young et al., 2015). 
Epidemiological studies have found no association between vitamin C and leiomyoma risk 
(Martin et al., 2011; Wise et al., 2011). This appears to be the first time vitamin C has been 
linked to leiomyomagenesis, and thus its significance requires further clarification. 
2.2. Metabolomic alterations in FH-deficient leiomyomas 
FH-deficient leiomyomas displayed dysregulation of a large number of metabolites, with 
the majority of them elevated when compared to the normal myometrium, suggesting severe 
deregulation in cellular metabolism. These leiomyomas had elevated levels of fumarate and 
other TCA cycle intermediates including malate, succinate, α-ketoglutaric acid (αKG), and 
homocitrate. Accumulation of fumarate and succinate in FH-deficient cells and tissues has 
been reported previously, but the results regarding the levels of malate, αKG, and citrate 
have been contradictory (Pollard et al., 2005; Frezza et al., 2011; Tong et al., 2011; Adam 
et al., 2013; Yang et al., 2013; Zheng et al., 2013). In addition, these TCA cycle metabolites 
accumulate in physiological fluids of patients with a rare autosomal recessive disorder, 
congenital fumarase deficiency (Allegri et al, 2010; Tregoning et al, 2013). One suggested 
route for the production of citrate, acetyl coenzyme A, and the remaining four-carbon TCA 
cycle intermediates in FH-deficient cells is glutamine-dependent reductive carboxylation of 
αKG, but contradicting data also exists (Frezza et al., 2011; Mullen et al., 2012; Adam et 
al., 2013). Studies on FH-deficient leiomyoma cells are required to determine whether this 




Accumulated fumarate is considered to drive tumorigenesis by activating NRF2, which 
results in the activation of the NRF2-mediated Oxidative Stress Response pathway and the 
redirection of glucose and glutamine into anabolic pathways such as the pentose phosphate 
pathway (PPP) (Adam et al., 2011; Kinch et al., 2011; Mitsuishi et al., 2012; Gorrini et al., 
2013; Mehine et al., 2016). In this work, FH-deficient leiomyomas displayed several 
metabolic alterations known to be affected by NRF2 including enhanced PPP flux and 
altered heme metabolism, changes which have been observed previously in FH-deficient 
cells (Frezza et al., 2011; Yang et al., 2013). The enhanced PPP generates NADPH, which 
is needed for reductive carboxylation of glutamine-derived αKG, synthesis of fatty acids, 
and protection against oxidative stress; processes important for proliferative cells. FH-
deficient cells seem to boost the removal of accumulated TCA cycle metabolites through 
enhanced heme metabolism, which excretes TCA-cycle-derived carbon as bilirubin (Frezza 
et al., 2011). Inhibition of this process is synthetic lethal with FH deficiency, highlighting 
it as a potential treatment target. 
FH-deficient leiomyomas displayed uniquely high levels of argininosuccinate and N6-
succinyladenosine (S-ado). Argininosuccinate is normally produced in the urea cycle by 
argininosuccinate lyase (ASL) and is further converted into fumarate and arginine, but to 
detoxify the accumulating fumarate, the enzyme function is reversed (Adam et al., 2013; 
Zheng et al., 2013). FH-deficient kidney cancers employ exogenous arginine to produce 
argininosuccinate; blocking this mechanism reduces proliferation of FH-deficient cells, 
suggesting that the arginine pathway is essential for the growth of FH-deficient tumors. 
Furthermore, FH-deficient mice secrete argininosuccinate into their urine, as do FH-
deficient cell lines into their growth media (Zheng et al., 2013). Argininosuccinate may 
therefore emerge as a robust metabolic biomarker, and arginine metabolism as a treatment 
target, for HLRCC-associated tumors. S-ado accumulation in FH-deficient cells likely 
derives from inhibition of adenylosuccinate lyase (ADSL), which catalyzes two reactions 
in purine de novo synthesis both producing fumarate as a side product (Jurecka et al., 2015). 
S-ado is formed through dephosphorylation of adenylosuccinate, elevated levels of which 
have been observed in FH-deficient kidney specimens from mice and in physiological fluids 
of congenital fumarase deficiency patients, further supporting our results (Allegri et al, 
2010; Adam et al, 2013; Tregoning et al, 2013). The potential tumorigenic role of S-ado 
and its utility as a biomarker require further exploration. 
The two leiomyomas overexpressing HMGA2 displayed mainly an accumulation of 
metabolites. Although the number of these tumors was too small to derive any conclusions, 
they displayed some similarities with FH-deficient leiomyomas including the accumulation 
of plasmalogens and diacylglycerols. These lipids are components of cell membranes that 
affect the membrane properties and facilitate various signaling processes (Gómez-
Fernández and Corbalán-García, 2007; Braverman and Moser, 2012). In addition, both of 
these leiomyoma subtypes showed accumulation of polyamines. Elevated levels of 
polyamines have been implicated in the induction of cell proliferation and the reduction of 
apoptosis (Gerner and Meyskens, 2004). Furthermore, targeting their metabolism may 
prove an effective therapy or, more importantly, a prevention mechanism for these 
leiomyomas, as a prior study demonstrated that treatment with difluoromethylornithine, a 





growth (Broaddus et al., 2004; Gerner and Meyskens, 2004). These results require 
confirmation in a larger sample set, but provide new insight into the molecular mechanism 
underlying these tumors and potential targets for limiting their growth.
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CONCLUDING REMARKS AND 
FUTURE PERSPECTIVES 
This thesis is based on the groundbreaking finding of MED12 mutations in leiomyomas; 
this work validates and elucidates their role and clinical features. In view of all the data, 
MED12 mutations are oncogenic and drive the growth of the vast majority of leiomyomas. 
Furthermore, MED12-mutation-positive lesions represent a molecularly and clinically 
distinct subgroup of leiomyomas, suggesting that the molecular background of these tumors 
should be taken into consideration in basic research, drug development, and when targeted 
treatments emerge, in clinical practice as well. The emergence of animal and cell models 
for MED12-mutation-positive tumors is critical for advancing our understanding of the 
molecular basis for the tumorigenic potential of these mutations and for developing targeted 
therapies. The high frequency of MED12-hotspot mutations in female-steroid-hormone-
dependent tumors is striking; further research into how MED12 mutations relate to steroid 
hormones is required.  
The main genetic drivers of leiomyomagenesis have now been identified; this thesis reveals 
the metabolomic heterogeneity of leiomyomas and contributes to our understanding of the 
pathophysiology underlying their molecular subtypes. Additional studies are required for a 
deeper understanding of how these mutations arise and drive tumorigenesis, however. In 
addition, as the genetic driver still remains unidentified for a small subset of conventional 
leiomyomas and in particular for a large proportion of leiomyoma variants, large sample 
sets are warranted to obtain sufficient numbers of tumors harboring these rarer events. 
Further work addressing the clinical features of all molecular subtypes of leiomyomas is 
required to assess which subtypes may be induced by inflammation or infection, and 
whether the different subtypes respond differently to treatments, such as ulipristal acetate, 
and other hormonal changes. The molecular classification of leiomyomas has raised a 
demand for biomarkers for research and clinical purposes. On the other hand, studying the 
molecular changes shared by all leiomyoma subtypes may result in the discovery of a 
therapy effective against all of them. 
The genetic and environmental predisposition to the different molecular subtypes of 
leiomyomas requires clarification. Understanding the mechanisms that lead to the 
emergence and growth of leiomyomas is crucial in order to identify means to prevent the 
development of these lesions. The most effective approach to reduce the morbidity and costs 
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